Advertisement

You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

November 21, 2014

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

FDA reviews trial results of long-term dual antiplatelet therapy

FDA announced that it will review results from a clinical trial showing that long-term dual antiplatelet therapy decreased the risk of heart attacks and clot formation in stents, but there was an increased overall risk of death compared to 12 months of treatment. » Will patients benefit from this combination therapy?

Trial shows cholesterol-lowering benefit of statin plus ezetimibe

In high-risk patients with acute coronary syndromes (ACS), administration of the cholesterol-lowering agent Vytorin, a combination of the non-statin ezetimibe (Zetia) and simvastatin, may be a more useful strategy for lowering LDL cholesterol and reducing the risk of cardiovascular events than statin use alone would be. » Read more data presented at the American Heart Association's Scientific Sessions in Chicago

Continuing Education

MTM essentials for weight management

This month's CE activity is part of a year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease. From February 2014 through January 2015, pharmacists can earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to educate pharmacists about the prevalence, health consequences, and nonpharmacologic and pharmacologic treatment options for obesity, with a focus on the recommendations made in the 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exam and earn up to 2 CPE credits, click here to log in with the session code 14DT12-FKX42.


Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

Dabrafenib-trametinib combo linked to improved overall survival in melanoma patients compared to vemurafenib monotherapy

Treatment with the combination of trametinib (Mekinist) and dabrafenib (Tafinlar) significantly improved overall survival (OS) compared to vemurafenib monotherapy in previously untreated patients with BRAF V600E/K mutation-positive metastatic melanoma, without increased overall toxicity, according to a study published in the New England Journal of Medicine. » Read here for more study results

 

RELATED ARTICLES

FDA approves clot-busting vorapaxar

Investigational ACL inhibitor shows promise in lowering LDL cholesterol

RESOURCES

Latest Clinical News

Powered by Modern Medicine Advanstar Medical Communications Group